Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)-Reference-Cited by-同舟云学术

Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)

Published:2024-04-30 Issue: Volume: Page:
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Jaïs Marie,Roblot Pascal,Maillot François,Hamidou Mohamed,Enfrein Antoine,Lescoat Alain,Puyade Mathieu,Martin Mickaël^ORCID,Perier Amandine

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00296-024-05589-2.pdf

Reference26 articles.

1. Gladman DD, Urowitz MB, Rahman P et al (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955–1959

2. Mathian A, Pha M, Haroche J et al (2020) Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomized clinical trial. Ann Rheum Dis 79:339–346. https://doi.org/10.1136/annrheumdis-2019-216303

3. Ji L, Xie W, Zhang Z (2021) Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology 60:5517–5526. https://doi.org/10.1093/rheumatology/keab149

4. Wiebe E, Huscher D, Schaumburg D et al (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis 81:1313–22. https://doi.org/10.1136/annrheumdis-2022-222339

5. Doria A, Gatto M, Zen M et al (2014) Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 13:770–7. https://doi.org/10.1016/j.autrev.2014.01.055